We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Surface Ophthalmics announced the first patient has been dosed in the Phase II clinical trial for its investigational product SURF-200 (betamethasone in Klarity® vehicle) for the treatment of acute dry eye.